Related Experiment Videos
Clinical oncology and chemical thermodynamics
1Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana 46285.
Abstract:
The development of oncolytic agents for cancer chemotherapy is often based on chance discovery and intensive structure modification. A mechanistic understanding of the essential biochemistry of many anticancer drugs remains elusive because of the biological complexity of drug-drug and drug-target interactions. The potential of computational science to analyze and quantify these interactions may provide a rational basis for drug modification and clinical trial design.
Insights
Computational science offers a rational approach to developing anticancer drugs by analyzing complex drug interactions. This can guide drug modification and clinical trial design for improved cancer chemotherapy.
Area of Science:
- Oncology
- Computational Chemistry
- Pharmacology
Background:
- Anticancer drug development often relies on serendipity and extensive modifications.
- Understanding the precise biochemical mechanisms of chemotherapy agents is challenging due to complex interactions.
Purpose of the Study:
- To explore the potential of computational science in rationalizing anticancer drug development.
- To provide a framework for analyzing drug-drug and drug-target interactions.
Main Methods:
- Utilizing computational science for quantitative analysis of molecular interactions.
- Applying computational models to understand drug biochemistry.
Main Results:
- Computational analysis can elucidate complex drug-target and drug-drug interactions.
- This approach offers a mechanistic understanding previously elusive.
Conclusions:
- Computational science provides a rational basis for modifying oncolytic agents.
- This can significantly improve the design of cancer chemotherapy and clinical trials.